 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Gilead Sciences, Inc.
 |
Gilead Sciences, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Gilead says to sell Proligo, post Q3 gain Aug 22 2001 01:52 PM PDT
FDA panel to review Gilead HIV drug Aug 21 2001 03:02 PM PDT
Hot stocks highlights -- July 27 Jul 27 2001 07:15 AM PDT
Gilead Sciences Q2 loss is wider than expected Jul 26 2001 01:38 PM PDT
> More WIRE STORIES about this company
PROFILE |
 |
Gilead Sciences has biotech balms for infectious diseases (including the flu and infections related to AIDS) and cancer. The company's Tamiflu went on the market in time for the 1999-2000 flu season, but its biggest seller is AmBisome, which is used to treat systemic fungal infections such as accompany AIDS. Other products on the market are DaunoXome, a treatment for Kaposi's sarcoma, and VISTIDE, to treat eye infections. Gilead has products in the pipeline for hepatitis B and various cancers. The company has marketing alliances with such heavyweights as GlaxoSmithKline, Pharmacia, and Sumitomo Pharmaceuticals. Former chairman Donald Rumsfeld resigned to become the Bush administration's Secretary of Defense.
COMPETITION |
 |
Bristol-Myers Squibb Company (BMY)
Merck & Co., Inc. (MRK)
Shire BioChem Inc. (dossier)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 195.60
1-Yr. Sales Growth: 15.7%
Employees: 850
Revenue per employee: $230,117.65
KEY PEOPLE |
 |
John C. Martin
CEO
Mark L. Perry
CFO
CONTACT INFO |
 |
333 Lakeside Dr.
Foster City, CA 94404
US
Phone: 650-574-3000
Fax: 650-578-9264
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |